这是一篇来自已证抗体库的有关人类 mesothelin的综述,是根据10篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合mesothelin 抗体。
mesothelin 同义词: MPF; SMRP

赛默飞世尔
domestic rabbit 单克隆(SP74)
  • 免疫组化基因敲除验证; 人类; 1:50; 图 6a, 6b
  • 免疫组化-石蜡切片; 人类; 1:50; 图 1b, 5b, 5c, 7a, 7b
赛默飞世尔 mesothelin抗体(Thermo Fisher, SP74)被用于被用于免疫组化基因敲除验证在人类样本上浓度为1:50 (图 6a, 6b) 和 被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 1b, 5b, 5c, 7a, 7b). Int J Mol Sci (2022) ncbi
domestic rabbit 单克隆(SP74)
  • 免疫细胞化学基因敲除验证; 人类; 1:50; 图 2e
  • 免疫组化-石蜡切片; 人类; 1:50; 图 1e
  • 免疫细胞化学; 人类; 1:50; 图 2e
赛默飞世尔 mesothelin抗体(Thermo Fisher, MA5-16378)被用于被用于免疫细胞化学基因敲除验证在人类样本上浓度为1:50 (图 2e), 被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 1e) 和 被用于免疫细胞化学在人类样本上浓度为1:50 (图 2e). Oncogenesis (2020) ncbi
小鼠 单克隆(5B2)
  • 免疫组化-石蜡切片; 人类; 图 3f
赛默飞世尔 mesothelin抗体(Thermo Fisher, MS-1320-S0)被用于被用于免疫组化-石蜡切片在人类样本上 (图 3f). JCI Insight (2018) ncbi
小鼠 单克隆(5B2)
  • 免疫组化-石蜡切片; 人类; 1:10; 图 2
赛默飞世尔 mesothelin抗体(Labvision, MA5-11918)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:10 (图 2). Pathol Res Pract (2016) ncbi
小鼠 单克隆(5B2)
  • 免疫组化; 人类; 1:30; 图 4b
赛默飞世尔 mesothelin抗体(Thermo Scientific, MS-1320)被用于被用于免疫组化在人类样本上浓度为1:30 (图 4b). Cancer Immunol Res (2015) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 单克隆
  • 免疫组化; 人类; 1:200; 图 2a
艾博抗(上海)贸易有限公司 mesothelin抗体(Abcam, ab133489)被用于被用于免疫组化在人类样本上浓度为1:200 (图 2a). Front Oncol (2022) ncbi
domestic rabbit 单克隆(SP74)
  • 免疫组化-石蜡切片; 人类; 图 1
艾博抗(上海)贸易有限公司 mesothelin抗体(Abcam, ab93620)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1). J Clin Invest (2017) ncbi
圣克鲁斯生物技术
小鼠 单克隆(G-1)
  • 免疫印迹; 人类; 1:250; 图 3a
圣克鲁斯生物技术 mesothelin抗体(Santa Cruz, sc-271540)被用于被用于免疫印迹在人类样本上浓度为1:250 (图 3a). PLoS ONE (2017) ncbi
Rockland Immunochemicals
小鼠 单克隆(MN-1)
  • 免疫印迹; 人类; 图 1c
Rockland Immunochemicals mesothelin抗体(Rockland Immunochemicals, 200-301-A88)被用于被用于免疫印迹在人类样本上 (图 1c). Mol Cancer Ther (2016) ncbi
徕卡显微系统(上海)贸易有限公司
小鼠 单克隆(5B2)
  • 免疫组化-石蜡切片; 人类; 1:30
徕卡显微系统(上海)贸易有限公司 mesothelin抗体(Novocastra, 5B2)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:30. Hum Pathol (2014) ncbi
文章列表
  1. Li Y, Tian W, Zhang H, Zhang Z, Zhao Q, Chang L, et al. MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer. Front Oncol. 2022;12:830570 pubmed 出版商
  2. Nunes M, Pacheco F, Coelho R, Leit xe3 o D, Ricardo S, David L. Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer. Int J Mol Sci. 2022;23: pubmed 出版商
  3. Coelho R, Ricardo S, Amaral A, Huang Y, Nunes M, Neves J, et al. Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis. 2020;9:61 pubmed 出版商
  4. Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3: pubmed 出版商
  5. Smith T, Moffett H, Stephan S, Opel C, Dumigan A, Jiang X, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017;127:2176-2191 pubmed 出版商
  6. De Santi C, Vencken S, Blake J, Haase B, Benes V, Gemignani F, et al. Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing. PLoS ONE. 2017;12:e0170999 pubmed 出版商
  7. Awuah P, Bera T, Folivi M, Chertov O, Pastan I. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Mol Cancer Ther. 2016;15:1648-55 pubmed 出版商
  8. Ibrahim D, Abouhashem N. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis. Pathol Res Pract. 2016;212:288-93 pubmed 出版商
  9. Wang E, Wang L, Tsai C, Bhoj V, Gershenson Z, Moon E, et al. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res. 2015;3:815-26 pubmed 出版商
  10. Ordonez N, Sahin A. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol. 2014;45:1529-40 pubmed 出版商